Literature DB >> 14712466

Multicentric Castleman's disease associated with glomerular microangiopathy and MPGN-like lesion: does vascular endothelial cell-derived growth factor play causative or protective roles in renal injury?

Aya Seida1, Jun Wada, Yoshitaka Morita, Masako Baba, Jun Eguchi, Norihisa Nishimoto, Takeshi Okino, Koichi Ichimura, Tadashi Yoshino, Hirofumi Makino.   

Abstract

A 52-year-old Japanese man presented with fever spikes, generalized fatigue, anorexia, and anasarca. The patient was referred for the evaluation of fever of unknown origin in association with swelling of cervical, axillary, and inguinal lymph nodes. He also manifested nephrotic syndrome, acute renal failure, hepatosplenomegaly, massive pleural effusion, ascites, disseminated intravascular coagulation, and hypergammaglobulinemia. C-reactive protein was positive and plasma vascular endothelial cell-derived growth factor (VEGF) and serum interleukin-6 levels were markedly elevated. Lymph node biopsy results showed that findings were compatible with Castleman's disease of hyaline vascular type associated with interfollicular plasmacytosis. In conjunction with the clinical findings, a diagnosis of multicentric Castleman's disease was made. The patient underwent renal biopsy because of nephrotic syndrome, and the results showed proliferation of mesangial cells, lobulation of glomeruli, and tram track pattern of the capillary wall without immune complex deposition. Electron microscopy showed widening of the subendothelial space. No electron-dense deposits were present in both mesangial and subendothelial regions. Pathologic features were compatible with glomerular microangiopathy and membranoproliferative glomerulonephritis-like lesions. With corticosteroid therapy, systemic symptoms disappeared; both VEGF and interleukin-6 levels were normalized, and he went into complete remission of nephrotic syndrome. In this article, the role VEGF plays in the pathogenesis of nephrotic syndrome and glomerular microangiopathy is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14712466     DOI: 10.1053/j.ajkd.2003.09.023

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  14 in total

Review 1.  Renal complications of Castleman's disease: report of two cases and analysis of 75 cases.

Authors:  Xiang-Gui Yuan; Wen Hu; Fei-Fei Chen; Bin-Feng Huang; Xiao-Ying Zhao
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

2.  Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease.

Authors:  Akito Maeshima; Masao Nakasatomi; Daizo Henmi; Shin Yamashita; Yoriaki Kaneko; Takashi Kuroiwa; Keiju Hiromura; Yoshihisa Nojima
Journal:  CEN Case Rep       Date:  2012-03-17

Review 3.  Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.

Authors:  Shou-Hui Zhu; Yong-Hua Yu; Yong Zhang; Ju-Jie Sun; Da-Li Han; Jia Li
Journal:  Med Oncol       Date:  2013-02-12       Impact factor: 3.064

4.  Successful stabilisation of nephropathy in a patient with POEMS (polyneuropathy, organomegaly, endocrinopathy, M-band, skin changes) syndrome on treatment with mycophenolate and steroids: a case report.

Authors:  Gareth J Rosser; Pablo Garcia Reitböck; Martin C Gray; Paul Warwicker
Journal:  J Med Case Rep       Date:  2010-02-22

Review 5.  Multicentric Castleman's disease: a challenging diagnosis.

Authors:  Györgyi Műzes; Ferenc Sipos; Judit Csomor; Lídia Sréter
Journal:  Pathol Oncol Res       Date:  2013-03-21       Impact factor: 3.201

Review 6.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

7.  Interleukin-6 receptor inhibition with tocilizumab in various renal involvements associated with multicentric Castleman's disease: a report of three cases.

Authors:  Hirotaka Komaba; Takashi Nakazawa; Yutaka Yamaguchi; Shunichi Kumagai; Masafumi Fukagawa
Journal:  NDT Plus       Date:  2008-10-08

8.  Serial Manifestation of Acute Kidney Injury and Nephrotic Syndrome in a Patient with TAFRO Syndrome.

Authors:  Seigo Ito; Takahiro Uchida; Hiroki Itai; Aoi Yamashiro; Akira Yamagata; Hidehito Matsubara; Toshihiko Imakiire; Hideyuki Shimazaki; Hiroo Kumagai; Naoki Oshima
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

9.  A rare case of renal thrombotic microangiopathy associated with Castleman's disease.

Authors:  Anubha Mutneja; L Nicholas Cossey; Helen Liapis; Ying Maggie Chen
Journal:  BMC Nephrol       Date:  2017-02-10       Impact factor: 2.388

10.  TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.

Authors:  Yoshikuni Nagayama; Mizuki Yamano; Motoka Yagame; Tomoyuki Nariyama; Mikiko Takahashi; Masashi Kawamoto; Katsuyuki Matsui
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.